GlassScriptPhysician profile
Susan R Scheck
NPI 1831674480
$2,917.87
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $446 · 2023: $1,733 · 2024: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.24 |
| Education | $176.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $245.99 | 2022-2023 | Tukysa, Padcev, Adcetris |
| Abbvie INC. | $241.92 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $218.93 | 2022-2023 | Imfinzi, Tagrisso, Lynparza |
| Lilly USA, LLC | $214.00 | 2022-2023 | Verzenio, Jaypirca |
| Celgene Corporation | $187.23 | 2021-2023 | Pomalyst, Reblozyl |
| Novartis Pharmaceuticals Corporation | $147.08 | 2023-2024 | |
| Incyte Corporation | $141.99 | 2023-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $137.63 | 2022-2024 | Hyqvia, Ninlaro, Iclusig |
| Beigene USA, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.47 | 2022 | |
| Merck Sharp & Dohme LLC | $116.54 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $112.70 | 2023 | Darzalex, Tecvayli, Imbruvica |
| Amgen INC. | $109.22 | 2022-2023 | Blincyto, Kyprolis, Lumakras |
| Mirati Therapeutics, INC. | $92.67 | 2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $87.01 | 2023 | Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $67.59 | 2022-2023 | Cosela |
| Pharmaessentia USA Corporation | $66.54 | 2022-2024 | Besremi |
| Pfizer INC. | $59.75 | 2023 | |
| Daiichi Sankyo INC. | $47.47 | 2022-2023 | Enhertu |
| Hologic Sales and Service, LLC | $47.37 | 2024 | Acessa Provu System, Coolseal Generator |
| Genzyme Corporation | $41.85 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $39.59 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.91 | 2023 | |
| Alexion Pharmaceuticals, INC. | $25.13 | 2023 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $24.91 | 2024 | Cosela |
| Aveo Pharmaceuticals, INC. | $24.91 | 2023 | Fotivda |
| Astellas Pharma US INC | $23.63 | 2021 | |
| Gilead Sciences, INC. | $22.02 | 2023 | Trodelvy |
| Emd Serono, INC. | $21.82 | 2023 | Bavencio |
| Eisai INC. | $19.40 | 2024 | |
| Morphosys, US INC. | $19.40 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $16.40 | 2023 | Imbruvica |
| Immunogen, INC. | $15.80 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Scheck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.